Gain insights into the cutting-edge clinical trials market for Benign Prostatic Hyperplasia (BPH). Discover innovative treatments, therapies, and research shaping the future of BPH management in 2023. Pioneering towards enhanced prostate health.

For more sponsor type insights into the Benign Prostatic Hyperplasia clinical trials market, download a free report sample

The leading sponsors in the Benign Prostatic Hyperplasia clinical trials market are GSK plc, Mayne Pharma Group Ltd, Kissei Pharmaceutical Co Ltd, Astellas Pharma Inc, Fimei SpA, Eli Lilly and Co, C. H. Boehringer Sohn AG & Co KG, Glanbia Nutritionals Inc, Teva Pharmaceutical Industries Ltd, and Sanofi. Out of them, GSK plc has conducted the highest number of Benign Prostatic Hyperplasia clinical trials. 

The key sponsor types in the Benign Prostatic Hyperplasia clinical trials market are institution, company, and the government. Out of them, company dominates the market.